Clinical Trial

Knowledge of 18-19 Years Old About Papillomavirus and HPV Vaccination

Study acronym: CO-HPV
Completed
View on ClinicalTrials.gov →
Summary
Today, cancers associated with papillomavirus infection affect 6,300 new people each year in France, men and women combined. The papillomavirus vaccine is currently the only vaccine that protects against HPV-associated cancers. However, in its report on vaccination coverage for 2024, Santé Publique France reveals that 41.5% and 37.4% of the 18- and 19-year-old French population respectively have a complete vaccination schedule. Information, education and communication about HPV are essential to enable the entire population to make informed and responsible decisions about HPV. Increasing information and immunization coverage for papillomavirus is part of the government's ambitious health plans with the national sexual health strategy and college vaccination campaign.
Trial Details
NCT Number NCT07418203
Lead Sponsor Université de Reims Champagne-Ardenne
Conditions Human Papillomavirus
Enrollment 29 participants
Start Date 2024-12-01
Primary Completion 2025-02-01 (estimated)
Study Completion 2025-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-18